Catalytic domain variants of activated FVII (FVIIa) with enhanced hemostatic properties are highly attractive for the treatment of bleeding disorders via gene-based therapy. To explore this in a hemophilic mouse model, we characterized two variants of murine activated FVII (mFVIIa-VEAY and mFVIIa-DVQ) with modified catalytic domains, based on recombinant human FVIIa (rhFVIIa) variants. Using purified recombinant proteins, we showed that murine FVIIa (mFVIIa) and variants had comparable binding to human and murine tissue factor (TF) and exhibited similar extrinsic coagulant activity. In vitro in the absence of TF, the variants showed a 6-17 fold enhanced proteolytic and coagulant activity relative to mFVIIa, but increased inactivation by antithrombin. Gene delivery of mFVIIa-VEAY resulted in long-term, effective hemostasis at 5-fold lower expression levels relative to mFVIIa in hemophilia A mice or in hemophilia B mice with inhibitors to Factor IX. However, expression of mFVIIa-VEAY at 14-fold higher than therapeutic levels resulted in a progressive mortality to 70%, within 6 weeks following gene delivery. These results are the first demonstration of the hemostatic efficacy of continuous expression, in the presence or absence of inhibitors, of a high-activity gene-based FVIIa variant in an animal model of hemophilia.
ABSTRACT
Catalytic domain variants of activated FVII (FVIIa) with enhanced hemostatic properties are highly attractive for the treatment of bleeding disorders via gene-based therapy. To explore this in a hemophilic mouse model, we characterized two variants of murine activated FVII (mFVIIa-VEAY and mFVIIa-DVQ) with modified catalytic domains, based on recombinant human FVIIa (rhFVIIa) variants. Using purified recombinant proteins, we showed that murine FVIIa (mFVIIa) and variants had comparable binding to human and murine tissue factor (TF) and exhibited similar extrinsic coagulant activity. In vitro in the absence of TF, the variants showed a 6-17 fold enhanced proteolytic and coagulant activity relative to mFVIIa, but increased inactivation by antithrombin. Gene delivery of mFVIIa-VEAY resulted in long-term, effective hemostasis at 5-fold lower expression levels relative to mFVIIa in hemophilia A mice or in hemophilia B mice with inhibitors to Factor IX. However, expression of mFVIIa-VEAY at 14-fold higher than therapeutic levels resulted in a progressive mortality to 70%, within 6 weeks following gene delivery. These results are the first demonstration of the hemostatic efficacy of continuous expression, in the presence or absence of inhibitors, of a high-activity gene-based FVIIa variant in an animal model of hemophilia.
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INTRODUCTION
Over the past three decades, discoveries in multiple disciplines have been instrumental in the molecular dissection of hemophilia. These resulted in the development of novel therapies for the disease, including more effective treatment for the most serious complication in factor replacement, the development of inhibitory antibodies to Factor VIII (FVIII) or IX (FIX). In particular, rhFVIIa (commercially known as NovoSeven® [Novo Nordisk, Denmark]) has a proven record of successful treatment for hemophilia patients with inhibitors, by providing localized hemostasis when administered at supra-physiological doses of 90-110 µg/kg. 1 However, its short plasma half-life (2.7 hours) necessitates frequent infusions resulting in high treatment costs 2 and preventing its use as a universal hemostatic agent.
For pharmacologic intervention, efforts to enhance the procoagulant activity of rhFVIIa have focused on chemical modification/formulation 3, 4 or the rational design of novel, highspecific activity variants of rhFVIIa. This has been achieved by enhancing the phospholipid binding or increasing the catalytic activity of rhFVIIa. [5] [6] [7] [8] Although data from human subjects suggest that a single-dose of a rhFVIIa variant (rhFVIIa-DVQ, also known as NN1731) with enhanced, TF-independent activity is safe 9 , efficacy and long-term safety data in hemophilic patients are limited. Moreover, the majority of its in vivo efficacy data have been derived using non-homologous animal models in short-term studies, where potential species incompatibilities between human FVIIa and endogenous (animal) TF 10 may affect the hemostatic outcomes. 11, 12 As an alternative to rhFVIIa infusion, we have demonstrated in animal models the efficacy of gene-based FVIIa therapy for inherited bleeding disorders. In a pilot study, we generated a murine Factor VII (mFVII) transgene (mFVII-2RKR) that can be secreted in its
For personal use only. on August 31, 2017 . by guest www.bloodjournal.org From active form (mFVIIa) and, following continuous expression via viral vector mediated gene delivery, effect hemostasis in vivo in hemophilic mice. 13, 14 Moreover, in a multi-year study, we confirmed our approach in hemophilic dogs using canine FVII-2RKR (cFVIIa) as a transgene and demonstrated the complete elimination of spontaneous bleeds, a characteristic disease feature of these animals, without any evidence of thrombosis. 15 Although the adeno-associated virus (AAV) serotype 8 (AAV8) vector utilized in that study was the most efficient choice for expression 16 
METHODS

Plasmid construction and AAV vector production
The plasmid vectors for mFVII, mFVIIa and the liver-specific, adeno-associated virus (AAV) vector plasmid backbone have been previously described.
14 The mFVIIa-DVQ and VEAY variants were constructed by PCR mutagenesis and helper-free, recombinant AAV virus vector production was performed as previously described. 14 Vector genome (vg) titering for each construct was performed side-by-side in duplicate and confirmed by slot-blot as well as silver staining.
Recombinant proteins and purification
Stable cell lines expressing mFVII, mFVIIa, mFVIIa-DVQ or mFVIIa-VEAY containing a Cterminal epitope tag were established as previously described. 14 
Coagulation assays
For personal use only. on August 31, 2017 . by guest www.bloodjournal.org From Prothrombin time (PT) and activated partial thromboplastin time (aPTT) assays on plasma, cell culture supernatants, and purified proteins were determined as previously described 14 Recombinant AAV delivery and collection of mouse plasma samples were performed as
For personal use only. on August 31, 2017 . by guest www.bloodjournal.org From previously described. 15 The tail-clip and FeCl 3 assay were performed at or after 7 weeks post AAV administration, as previously described. 13 Histologic analysis was performed on tissues fixed in 10% formalin overnight at 4ºC, as previously described. 24 Staining for fibrin/ogen on paraffin sections was performed as previously described. 13 For immunofluorescence staining, paraffin sections were hydrated through xylene and graded alcohol and equilibrated in deionized water. Nonspecific binding was blocked with 3% BSA. They were then incubated with rat anti- 
Enzyme-linked immunosorbent assay (ELISA) for mFVIIa
Detection of free mFVIIa in the mouse plasma was performed using an enzyme-linked immunosorbent assay (ELISA), as previously described 13 with some modifications. Briefly, samples were diluted 20 or 80-fold in blocking buffer (1% skim milk in phosphate buffered saline [PBS] ) and incubation with the biotinylated Phe-Pro-Arg-chloromethylketone (Biotin-FPR-CMK, 77 µg/ml final concentration, Haematologic Technologies, Essex Junction, VT) was performed overnight at 4°C on an orbital shaker (300 rpm). Murine FVII/mFVIIa in the samples was captured using a custom rat anti-mFVII/a monoclonal antibody (Green Mountain Antibodies, Burlington, VT) coated at 10 µg/ml in 50 mM NaHCO 3 , pH9.6. This antibody was 
Generation of inhibitors to human FIX (hFIX)
Baseline mouse plasma samples were obtained following tail bleeding several days prior to the For personal use only. on August 31, 2017. by guest www.bloodjournal.org From
Statistical analysis and protein percentage identity calculation and homology-based modelling
Data were analyzed using a Mann-Whitney (non-parametric) test. Survival data analysis was performed using the log-rank (Mantel-Cox) test in the GraphPad Prism v5.0 software package (GraphPad Software, La Jolla, CA). In all tests, differences were considered significant at P < . 14 ) and generated mFVIIa-DVQ and mFVIIa-VEAY ( Figure 1 ).
Purified recombinant proteins exhibited the expected fragment sizes (Figure 2A ). Zymogen mFVII purified under identical conditions was in the single-chain form, indicating that there was no autoactivation during the purification process. Murine FVIIa as well as both mFVIIa variants were present in almost 100% active form ( Figure 2A ).
We subsequently investigated the binding of recombinant proteins to msTF or hsTF indirectly by measuring cleavage of a small peptidyl substrate (amidolytic activity of the FVIIa-TF complex). Murine FVIIa and its variants were stimulated in the presence of increasing concentrations of msTF or hsTF and showed similar binding compared to each other (Table 1) , although binding to hsTF was not as tight as previously reported using surface plasmon resonance. 10 Zymogen mFVII showed negligible amidolytic activity. Since the rhFVIIa-DVQ and rhFVIIa-VEAY exhibit enhanced intrinsic activity towards peptidyl and macromolecular substrates 7 , we determined the activity of the recombinant mFVII/FVIIa proteins towards macromolecular substrate (FX), in the absence of TF ( Figure 2B ). Human FX was used as a
For personal use only. on August 31, 2017. by guest www.bloodjournal.org From substitute for murine FX since the latter was not commercially available. Under those experimental conditions, compared to mFVIIa, both mFVIIa-VEAY and mFVIIa-DVQ exhibited enhanced rates of activated hFX (hFXa) generation (P < .03) that ranged from 8-fold (mFVIIa-VEAY) to 17.9-fold (mFVIIa-DVQ). In contrast, rhFVIIa exhibited a rate of hFXa generation similar to mFVIIa (P = .11) and zymogen mFVII showed substantially reduced proteolytic activity (P < .04 vs. mFVIIa). Together, these data demonstrate that the specific modifications present in the catalytic site of the mFVIIa variants do not alter binding to TF but substantially enhance their proteolytic activity, compared to mFVIIa.
mFVIIa variants exhibit enhanced in vitro coagulant activity
Next, we examined the coagulant activity of recombinant proteins using extrinsic (PT) and intrinsic (aPTT) coagulation pathway assays, compared to rhFVIIa (100%). As expected 14 , mFVIIa had similar extrinsic activity to rhFVIIa (91%), whereas mFVII had approximately 22% extrinsic activity ( Figure 2C ). When compared to mFVIIa, the mFVIIa-VEAY and mFVIIa-DVQ variants exhibited modestly reduced (P = .01) and elevated (P = .03) extrinsic activity, respectively ( Figure 2C ). However, in the intrinsic (TF-independent) clotting assay using human FVIII or FIX deficient plasmas, both mFVIIa variants showed increased activity in both plasmas (P < .002 vs. mFVIIa) ( Figure 2D ). The fold enhancement was not statistically different between FVIII and FIX deficient plasma (P > .07). Zymogen mFVII had minimal activity (<1%) and none of the recombinant proteins exhibited appreciable coagulant activity in hFX deficient plasma (data not shown). Similar results were obtained using mouse HA or HB plasma (data not shown). Both variants displayed enhanced inactivation in HA or HB mouse plasma in the order of mFVIIa-VEAY >> mFVIIa-DVQ > mFVIIa, that was antithrombin-dependent (Supplemental Figure 1 ), similar to previous observations with their human counterparts. 7 These data confirm the observed enhancement in proteolytic activity (vide supra) and indicate that mFVIIa-VEAY and mFVIIa-DVQ had essentially unaltered TF-dependent but substantially enhanced TFindependent coagulant activity compared to mFVIIa.
mFVIIa-VEAY normalizes the hemophilia A phenotype at greatly reduced AAV vector doses and expression levels
The inactivation profiles of the mFVIIa variants suggest that their improved hemostatic properties in vitro may not necessarily translate to enhanced hemostatic efficacy in vivo in a gene transfer setting. This is particularly relevant for mFVIIa-VEAY, which exhibited the fastest inactivation. We chose the mFVIIa-VEAY variant to demonstrate whether improved hemostatic effects can be observed with enhanced activity FVIIa variants even with unfavorable inactivation profiles. We constructed an AAV serotype 8 vector carrying either the mFVIIa or mFVIIa-VEAY transgene under the control of a liver-specific promoter/enhancer, as previously For
org From
Both cohorts exhibited long-term normalization of the hemophilic aPTT ( Figure 3B ; P > .05 for AAV-mFVIIa-VEAY [L] vs. AAV-mFVIIa at all timepoints). However, this was achieved at ~5 fold lower circulating protein levels for mFVIIa-VEAY compared to mFVIIa (0.6 ± 0.25 µg/ml vs. 3.0 ± 0.75 µg/ml at the expression plateau [4 weeks post AAV administration], respectively; P < .002). To further confirm this observation, we determined relative mRNA levels in the transduced mouse livers for each cohort (harvested after 14 weeks post AAV administration). Both cohorts exhibited increased mFVII/mFVIIa transcript levels compared to untreated mice but AAV-mFVIIa-VEAY (L) treated mice had ~10 fold lower levels than the AAV-mFVIIa treated mice (Supplemental Data Figure 2 ).
We subsequently investigated whether hemostatic efficacy with mFVIIa-VEAY can be achieved at these greatly reduced vector doses/expression levels compared to mFVIIa, using two in vivo hemostatic challenges. In the tail clip assay, both AAV-mFVIIa and AAV-mFVIIa-VEAY (L) mice exhibited a similar (P = .98) reduction in blood loss compared to untreated HA mice (P < .002 for either cohorts vs. HA) although not at levels seen with hemostatically normal mice ( Figure 3C ), similar to our previous observations. 13, 14 In another hemostatic challenge (FeCl 3 carotid artery injury), both AAV-mFVIIa and AAV-mFVIIa-VEAY (L) mice exhibited stable vessel occlusion within 5 minutes in 33% of the cases following FeCl 3 application, although partial occlusion was also observed in 2 out of 9 AAV-mFVIIa treated mice (Table 2 ).
In terms of safety, we did not observe any difference in levels of thrombin-antithrombin (TAT) complex for either cohort ( Figure 3D ).
To further investigate hemostatic efficacy of mFVIIa-VEAY in a setting of hemophilic inhibitors, we used a protocol ( Figure 4A ) to generate inhibitors to human FIX (hFIX) in HB mice. This resulted in induction of neutralizing antibodies as measured by a Bethesda assay Figure 4B ) as well as total anti-hFIX IgG ( Figure 4C , timepoints A-C). We subsequently administered low-dose AAV-mFVIIa-VEAY (3 x 10 10 vg/mouse), similar to those administered in HA mice (vide supra). Because the expressed mFVIIa-VEAY transgene product would result in erroneous Bethesda titer (since it is a clottingbased assay), we measured total anti-hFIX IgG following gene transfer as a surrogate test. We found that this was similar to pre-AAV infusion levels (weeks 4 and 9 vs. timepoint C, P ≥ .2) ( Figure 4C ). This indicates that the immune response to hFIX remained stable over the course of the experiment, following AAV administration. More importantly, AAV-mFVIIa-VEAY administration resulted in expression of mFVIIa-VEAY at ~1 µg/ml (assayed at 4 or 9 weeks post AAV administration) and near normalization of the aPTT as seen in HA mice ( Figure 4D , compare to Figure 3B ). This suggests that the presence of inhibitory antibodies does not change the hemostatic effects of mFVIIa-VEAY. This was also observed using AAV-mFVIIa injected at
x 10
12 vg/mouse (P. Margaritis, unpublished observations).
Together, these data suggest that, in agreement with the in vitro enhancement of intrinsic activity seen for mFVIIa-VEAY, in vivo hemostatic efficacy similar to mFVIIa can be achieved by lower level of expression of mFVIIa-VEAY and reduced AAV vector doses.
Overexpression of mFVIIa-VEAY in hemophilic mice results in rapid and increased mortality
Our previous observations of enhanced mortality in hemophilic mice overexpressing mFVIIa 
AAV-mFVIIa-VEAY [H]). In agreement
For personal use only. on August 31, 2017. by guest www.bloodjournal.org From with its enhanced intrinsic activity, the AAV-mFVIIa-VEAY (H) mice exhibited a sustained, supraphysiological reduction of the aPTT (~20 sec) ( Figure 5A ), well below levels observed for the other two cohorts (P < .001, compare to Figure 3B ). Steady-state expression of mFVIIa-VEAY in this cohort was ~8µg/ml (at 4 weeks post AAV) and reduction in blood loss following a tail clip assay was similar to the mFVIIa cohort ( Figure 5B , P = .28). Compared to hemostatically normal mice, the observed blood loss was not statistically different ( Figure 5B , P = .07). However, we observed a time-dependent increase in TAT complex formation ( Figure   5C ), and a rapid decrease in survival to 30% within the first 6 weeks post vector administration.
This was in contrast to untreated HA mice ( Figure 5D , P < .004) or the other cohorts (AAVmFVIIa and AAV-mFVIIa-VEAY [L]) that showed nearly 100% survival (data not shown) within the same experimental time period.
Histopathological examination was used to further investigate the cause of death in 6 mice in the AAV-mFVIIa-VEAY (H) cohort. Necropsy revealed no gross abnormalities and histological analyses in the spleen, liver or kidneys were normal compared to 6 untreated HA mice (data not shown). Major pathological findings were confined to the heart and lungs. We observed visible thrombi in the heart (6 out of 6 mice; Figure 6A -B), predominantly in the atria, as well as fibrosis (4 out of 6 mice) and occasional inflammatory cell infiltrates in the myocardium (2 out of 6 mice) (data not shown). In the lungs, we observed hemorrhage (5 out of 6 mice) as well as fibrin deposition that extended into the lung parenchyma ( Figure 6C-E) , that was absent in untreated HA controls ( Figure 6E ). These findings are similar to those observed previously in transgenic mice overexpressing mFVIIa 13 and, together with the elevated levels of TAT, pulmonary hemorrhage and fibrin deposition, are indicative of ongoing clot formation in the microcirculation as the most likely cause of death in these mice.
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DISCUSSION
The development of inhibitory antibodies against FVIII or FIX remains the most serious and most common complication of the current treatment of hemophilia by protein replacement. 31 Although treatment of inhibitor patients with bolus infusion of rhFVIIa is effective, frequent and high dose administration is necessary. As an alternative to bolus dosing, we have previously utilized gene delivery to continuously express an engineered activated FVII transgene and shown efficacy in small (murine) and large (canine) hemophilic models. 14, 15 In particular, multi-year expression of gene-based cFVIIa in hemophilic dogs was safe and resulted in elimination of spontaneous bleeds 15 that are characteristic in that model. 32 However, that study also underscored that improvements aimed to lower the hemostatically effective viral vector dose will be necessary prior to a human application.
We hypothesized that enhancement of the catalytic function of our FVIIa transgene would confer hemostatic efficacy at lower expression levels, and hence, reduce the vector dose.
The hemophilia mouse model, having well-established in vivo hemostatic endpoints, offers a convenient platform to systematically test this hypothesis. Here, we generated and characterized two murine FVIIa variants with enhanced intrinsic activity, that harbored corresponding mutations from enhanced activity human FVIIa variants with catalytic domain modifications. 7 A series of in vitro assays using purified recombinant proteins demonstrated that the murine FVIIa variants model their human counterparts in terms of enhanced activity as well as faster inhibition kinetics compared to the parent mFVIIa molecule. Although these opposing attributes may limit efficacy in a protein infusion setting, continuous expression of such FVIIa variants via gene delivery results in more favorable pharmacokinetic parameters. In the latter setting, hemostatic
For personal use only. on August 31, 2017. by guest www.bloodjournal.org From efficacy will be governed by the balance of expression level, rate of inhibition/secretion, clearance and extravascular dissemination of the expressed transgene. Our in vivo data using mFVIIa-VEAY clearly demonstrate that continuous expression can overcome its relatively unfavorable inactivation profile, and result in long-term hemostatic efficacy at lower expression levels and vector doses relative to the parent mFVIIa transgene. This was evident using two in vivo hemostatic challenge assays that demonstrated similar responses between HA mice expressing mFVIIa (~3 µg/ml) or mFVIIa-VEAY (~0.6 µg/ml). In addition, our data show that the presence of inhibitors to FIX did not appear to change the hemostatic effect of mFVIIa-VEAY. This is the first report for liver-directed FVIIa gene transfer in a hemophilia in vivo model complicated by inhibitors and lends further support for the therapeutic application of this approach. Clearly, the use of mFVIIa-DVQ or other variants with substantially enhanced activity would be expected to have more pronounced effects than mFVIIa-VEAY shown here.
We have previously shown that expression of mFVIIa in the range of 3-4 µg/ml in hemophilia B mice transgenic for mFVIIa results in mortality within months from birth that was positively associated with FX activity levels. 13 Here, expression of ~8µg/ml of mFVIIa-VEAY in hemophilia A mice, nearly 14-fold higher than therapeutic for this variant (~0.6 µg/ml), resulted in increased mortality but at a substantially shorter timeframe than previously seen (weeks vs. months 13 ). This observation thus identifies the enzymatic activity of the mFVIIa transgene as a risk factor, in addition to expression levels. In contrast, hemophilia A mice expressing ~0.6 µg/ml (mFVIIa-VEAY) did not show evidence of a prothrombotic phenotype within the duration of this study, suggestive of a relatively wide therapeutic window of effecting hemostasis with this enhanced variant of mFVIIa.
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Earlier clinical studies demonstrated an upper limit to doses of AAV serotype 2 vector that could be infused systemically into humans without triggering an immune response that destroyed the transduced cells. 33, 34 Thus the ability to achieve hemostasis at lower vector doses is a key step in successful translation to clinical studies for AAV-mediated gene transfer. The data presented here suggest a possible strategy to attain this goal with gene-based FVIIa therapy.
Clearly, the issue of safety is of prime importance when using enhanced activity FVIIa variants in this setting. However, there are two experimental observations that limit the potential for thrombotic complications: (1) reduced-level expression of mFVIIa-VEAY (~0.6 µg/ml vs. ~3 µg/ml for mFVIIa) in hemophilia A mice is hemostatically effective without thrombotic manifestations, as shown here; (2) long-term expression of cFVIIa at levels of ~2 µg/ml is efficacious and not associated with thrombosis in hemophilic dogs, a large animal model of hemophilia. 15 Based on these pre-clinical data, it seems unlikely that high expression levels of high-activity FVIIa transgene(s) will be necessary for hemostatic efficacy, thus minimizing the overall thrombotic risk. Employing inducible expression cassettes under the control of exogenously supplied activator drugs can further reduce this. Because of the high conservation between canine and human FVII (75% identity), our results also suggest that variants of cFVIIa with properties analogous to those described here can be generated. Further gene-transfer experiments in hemophilic dogs with such variants will address the issue of improvements in hemostatic efficacy as well as safety in a clinically-relevant animal model of hemophilia.
In addition to on-demand therapy, daily treatment of inhibitor patients prophylactically with rhFVIIa at pharmacologic doses for 3 months has been shown to reduce the number of bleeds, an effect that surprisingly extended in the 3-month follow-up. 35 The precise mechanism behind these extended hemostatic effects in the absence of administered rhFVIIa is unclear; it
For personal use only. on August 31, 2017. by guest www.bloodjournal.org From may involve the presence of rhFVIIa in the extravascular space 36 as has been shown in mice. 37, 38 Remarkably, we have previously shown that portal vein administration of AAV-cFVIIa at a subtherapeutic vector dose in a hemophilia B dog resulted in elimination of spontaneous bleeding episodes. 15 Although more confirmatory experiments are necessary, this suggests that continuous, low-level expression of FVIIa, as facilitated by gene transfer, may have long-term clinical benefits similar to a prophylactic rhFVIIa regimen. Within this context, the ability of enhanced activity FVIIa variants to effect hemostasis at reduced AAV vector doses, represents an additional improvement for this application that can be further tested in hemophilic dogs.
In conclusion, we have applied modifications in the catalytic domain of mFVIIa that Amino acid numbering refers to the mature secreted mFVII. 
